Show simple item record

Effect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis: a retrospective cohort study

dc.contributor.authorSchnippel, K
dc.contributor.authorNdjeka, N
dc.contributor.authorMaartens, G
dc.contributor.authorMeintjes, G
dc.contributor.authorMaster, I
dc.contributor.authorIsmail, N
dc.contributor.authorHughes, J
dc.contributor.authorFerreira, H
dc.contributor.authorPadanilam, X
dc.contributor.authorRomero, R
dc.contributor.authorTe Riele, J
dc.contributor.authorConradie, F
dc.date.accessioned2018-08-08T16:25:42Z
dc.date.available2018-08-08T16:25:42Z
dc.date.issued2018-07-09
dc.date.submitted2018-07-17
dc.identifier.citationEffect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis: a retrospective cohort study. 2018 Lancet Respir Meden
dc.identifier.issn2213-2619
dc.identifier.pmid30001994
dc.identifier.doi10.1016/S2213-2600(18)30235-2
dc.identifier.urihttp://hdl.handle.net/10144/619256
dc.description.abstractAddition of bedaquiline to treatment for multidrug-resistant tuberculosis was associated with an increased risk of death in a phase 2b clinical trial, resulting in caution from WHO. Following a compassionate access programme and local regulatory approval, the South African National Tuberculosis Programme began widespread use of bedaquiline in March, 2015, especially among patients with extensively drug resistant tuberculosis for whom no other effective treatment options were available. We aimed to compare mortality in patients on standard regimens with that of patients on regimens including bedaquiline.
dc.language.isoenen
dc.publisherElsevieren
dc.rightsArchived with thanks to Lancet Respiratory Medicineen
dc.titleEffect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis: a retrospective cohort studyen
dc.identifier.journalLancet Respiratory Medicineen
refterms.dateFOA2019-03-04T14:04:52Z
html.description.abstractAddition of bedaquiline to treatment for multidrug-resistant tuberculosis was associated with an increased risk of death in a phase 2b clinical trial, resulting in caution from WHO. Following a compassionate access programme and local regulatory approval, the South African National Tuberculosis Programme began widespread use of bedaquiline in March, 2015, especially among patients with extensively drug resistant tuberculosis for whom no other effective treatment options were available. We aimed to compare mortality in patients on standard regimens with that of patients on regimens including bedaquiline.


Files in this item

Thumbnail
Name:
Schnippel et al - 2018 - Effect ...
Size:
1.286Mb
Format:
PDF
Download

This item appears in the following Collection(s)

Show simple item record